The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Sustained action is needed now if we are to capitalise on the opportunity to eliminate viral hepatitis by 2030.
Epidemics of HIV and HPV are inherently interconnected – and when they meet in the context of weak health systems, their effects are amplifed.
On International Safe Abortion Day (28 September), we give an overview of the link between HIV and abortion and the need for broader sexual reproductive health rights for women.
Getting on top of the tuberculosis epidemic requires renewed attention, and bringing HIV out of isolation.
Opportunities to increase access to the hepatitis C cure exist – but strong political will is needed and many countries are failing to benefit from cheaper generics.
In their first treatment update since 2016, the World Health Organization (WHO) adopts a ‘treat all’ approach for hepatitis C, guided by the success of the HIV treatment experience.
Despite the huge human and economic toll, research into hepatitis B remains drastically underfunded, and was recently alikened to a neglected tropical disease. But hope for a cure is growing.
Increasing numbers of people co-infected with HIV and hepatitis C (HCV) are accessing treatment for HCV as antivirals become more effective – but challenges beyond increasing access, remain.
Interim clinical trial results offer hope to people living with hepatitis C who stand to benefit from reduced price treatment, including the 2.3 million people who have HIV co-infection.
In the run up to World Tuberculosis (TB) Day (March 24), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization reveal the region is off- target to end TB by 2030.
